 Positive Phase 3 data reported on Oct. 22, solidifies the approvability of SGX301 for CTCL treatment, an estimated 250M annual revenue opportunity, yet SNGXs valuation is only 55M. SGX942 for oral mucositis OM remains on track for Phase 3 results in December, and is now a call option that is not priced into the stock. 